ALCON PATANOL OPHTHALMIC ANTIHISTAMINE CLEARS FDA DEC. 18 FOR PREVENTION OF ALLERGIC ITCHING; PHASE IV STUDY LIKELY TO FOCUS ON NON-CAUCASIAN SUBJECTS
Executive Summary
Alcon will be re-entering the prescription ophthalmic antihistamine market following the approval of Patanol (olopatadine .1%) by FDA on Dec. 18.